Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 10/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 10/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | PDE6D | O43924 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6132706 | 0.88 | ALDH1A1 (0.46) | HDAC3HDAC8ALDH1A1PDE6DACACB | |
| SCHEMBL6133632 | 0.88 | HDAC3 (0.48) | HDAC3HDAC8ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL6132700 | 0.88 | ALDH1A1 (0.46) | HDAC3HDAC8ALDH1A1PDE6DACACB | |
| SCHEMBL6134832 | 0.87 | HDAC3 (0.49) | HDAC3HDAC8ALDH1A1PDE6DMAPT | |
| SCHEMBL6133982 | 0.87 | HDAC3 (0.46) | HDAC3HDAC8ALDH1A1ACACBMAPT | |
| SCHEMBL6135070 | 0.84 | ALDH1A1 (0.39) | HDAC3HDAC8ALDH1A1PDE6DACACB | |
| SCHEMBL6135042 | 0.84 | FDFT1 (0.44) | ALDH1A1MAPTSMN1; SMN2TSHRBCHE | |
| SCHEMBL6134902 | 0.83 | ALDH1A1 (0.50) | ALDH1A1PDE6DACACBMAPTSMN1; SMN2 | |
| SCHEMBL6132214 | 0.79 | MEN1 (0.43) | HDAC3HDAC8ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL6134644 | 0.79 | HDAC3 (0.51) | HDAC3HDAC8ALDH1A1PDE6DMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050261177-A1 | Compound | ASTELLAS PHARMA INC. (JP) | 2005-11-24 | — | — | US | disclosed |
| EP-1366066-A2 | CYCLOHEXAPEPTIDE HAVING ANTIMICROBIAL ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-12-03 | — | — | EP | disclosed |
| WO-2002072621-A2 | CYCLOHEXAPEPTIDE HAVING ANTIMICROBIAL ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261177-A1 | Compound | MANBA, MAN2B1, MAN2A1 | HDAC3 1145/4885HDAC8 2744/4885ALDH1A1 3841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.